- Global Pharma News & Resources

CO.DON AG: successful Annual General Meeting 2019

DGAP-News: CO.DON AG / Key word(s): AGM/EGM

17.06.2019 / 11:00
The issuer is solely responsible for the content of this announcement.

CO.DON: successful Annual General Meeting 2019

Teltow/Berlin, 17.06.2019 - This year's annual general meeting of CO.DON AG (ISIN DE000A1K0227) took place in Berlin on 12 June 2019 and was chaired by Professor Hans Bauerfeind, the Chairman of the Supervisory Board. Mr Tilmann Bur introduced himself to the shareholders and proxies in attendance as the CO.DON AG Executive Board member responsible for Sales and Marketing from 1 June 2019. Mr Ralf Jakobs, the spokesman of the company's Executive Board, then reported on the financial year 2018 and the company's performance in the opening months of the current financial year. "2018 was a year of upheaval and restructuring for CO.DON AG, in which we laid important foundations for the successful development of our company, including the definition of a corporate strategy for the next seven years, ensuring that our core product qualifies for reimbursement and initial steps in the political arena to establish and expand awareness of our method." Jacobs continued: "As a result of this turbulent year full of changes we can say today: We have been able to reposition CO.DON AG in 2018 and set it up for the future. We have established a stable business case for CO.DON AG for the years ahead, which we will build on deliberately and precisely." In his other comments he focused on a general presentation of CO.DON AG's plans for further development, particularly including the internationalisation of its business and the expansion of its product portfolio. The general discussion that followed showed the great interest of those present in the opportunities presented.

The voting shareholders attending, who represented 36.35 % of the 7,773,786 million voting shares, approved all the proposals put forward by company management. The members of the Executive Board and Supervisory Board were discharged of responsibility for the financial year 2018. Mazars GmbH & Co. KG Wirtschaftsprüfungs- und Steuerberatungsgesellschaft, Hamburg, was appointed as auditor of the financial statements and the consolidated financial statements for 2019. Resolutions were passed approving the revocation of Authorised Capital 2017 and the creation of new Authorised Capital 2019 and amending the articles of association to reflect modern corporate governance practice and contemporary communications methods. This concerned the term of office and resignations by Supervisory Board members, ways of passing resolutions, options for attending the annual general meeting, transferring the chair of the meeting to another person if the Supervisory Board Chairman is unable to attend, voting majorities, amendments relating to the financial statements and transfers to retained earnings and changes to the purpose of the company.

The final item on the agenda was a resolution on the supplementary motion concerning new elections to the Supervisory Board. Since Dr Wegener had resigned his seat on the Supervisory Board with effect from the close of the Annual General Meeting 2019, a proposal was made to the annual general meeting to elect his successor, in order to ensure that the Supervisory Board continued to have six members in accordance with the company's articles of association. Univ.-Prof. Dr.-Ing. Habil. Prof. e.h. Mult. Dr. h.c. Mult. Hans-Jörg Bullinger, Professor of Technology Management and former President of the Fraunhofer-Gesellschaft, resident in Stuttgart, was proposed to succeed Dr. Wegener. It was proposed that Prof. Bullinger's term of office should begin at the close of the Annual General Meeting 2019 and continue for the remainder of Dr Wegener's regular term of office, in accordance with the articles of association.

Professor Bullinger introduced himself to the shareholders and proxies present, outlining his biography and career and the reasons for his proposed involvement.

The annual general meeting approved the supplementary motion and elected Professor Bullinger to the Supervisory Board of CO.DON AG. Thanks and appreciation were expressed to Dr. Wegener for his long-standing contribution to the work of the Supervisory Board and the Executive Board.

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs (Spokesman), Tilmann Bur (COO).

Further information is available from

Investor Relations and Press Contact:

Matthias Meißner, M.A.
Tel. +49 (0)30 240352330
Fax +49 (0)30 240352309

17.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: CO.DON AG
Warthestraße 21
14513 Teltow
Phone: 03328 43460
Fax: 03328 434643
ISIN: DE000A1K0227
WKN: A1K022
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 825567

End of News DGAP News Service

Editor Details

Last Updated: 17-Jun-2019